Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt Inkomsten in het verleden
Verleden criteriumcontroles 5/6
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt has been growing earnings at an average annual rate of 25.4%, while the Pharmaceuticals industry saw earnings declining at 0.3% annually. Revenues have been growing at an average rate of 12.4% per year. Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt's return on equity is 19.6%, and it has net margins of 28.2%.
Belangrijke informatie
25.4%
Groei van de winst
25.6%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 6.0% |
| Inkomstengroei | 12.4% |
| Rendement op eigen vermogen | 19.6% |
| Nettomarge | 28.2% |
| Volgende winstupdate | 12 Nov 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 811,415 | 229,129 | 203,363 | 84,358 |
| 31 Mar 24 | 798,937 | 187,874 | 199,584 | 83,924 |
| 31 Dec 23 | 805,158 | 158,850 | 196,619 | 78,344 |
| 30 Sep 23 | 825,948 | 95,563 | 201,667 | 78,574 |
| 30 Jun 23 | 855,211 | 123,426 | 199,704 | 77,387 |
| 31 Mar 23 | 844,351 | 157,720 | 191,469 | 75,290 |
| 31 Dec 22 | 802,755 | 169,076 | 182,350 | 75,109 |
| 30 Sep 22 | 755,061 | 242,521 | 165,816 | 68,730 |
| 30 Jun 22 | 694,772 | 198,297 | 155,135 | 66,489 |
| 31 Mar 22 | 657,758 | 149,792 | 146,773 | 62,419 |
| 31 Dec 21 | 630,595 | 139,626 | 143,261 | 61,005 |
| 30 Sep 21 | 604,708 | 114,689 | 139,575 | 59,304 |
| 30 Jun 21 | 584,887 | 99,067 | 136,059 | 56,079 |
| 31 Mar 21 | 566,244 | 102,570 | 132,525 | 54,418 |
| 31 Dec 20 | 566,776 | 104,683 | 133,766 | 53,977 |
| 30 Sep 20 | 555,124 | 68,482 | 134,358 | 55,110 |
| 30 Jun 20 | 544,964 | 68,130 | 137,596 | 53,745 |
| 31 Mar 20 | 527,608 | 54,123 | 144,866 | 52,273 |
| 31 Dec 19 | 507,794 | 47,135 | 145,281 | 48,860 |
| 30 Sep 19 | 490,668 | 49,451 | 144,043 | 46,258 |
| 30 Jun 19 | 462,576 | 36,071 | 143,720 | 43,363 |
| 31 Mar 19 | 453,151 | 42,857 | 141,650 | 40,903 |
| 31 Dec 18 | 445,484 | 35,348 | 139,654 | 40,545 |
| 30 Sep 18 | 434,078 | 11,939 | 140,523 | 41,576 |
| 30 Jun 18 | 441,997 | 18,899 | 139,253 | 40,768 |
| 31 Mar 18 | 445,626 | 2,997 | 139,412 | 41,027 |
| 31 Dec 17 | 444,356 | 8,885 | 138,256 | 39,903 |
| 30 Sep 17 | 439,822 | 68,291 | 137,882 | 37,763 |
| 30 Jun 17 | 429,207 | 66,829 | 136,121 | 36,317 |
| 31 Mar 17 | 413,021 | 74,992 | 131,932 | 35,489 |
| 31 Dec 16 | 389,690 | 66,200 | 127,903 | 35,153 |
| 30 Sep 16 | 372,689 | 52,016 | 122,486 | 32,401 |
| 30 Jun 16 | 368,539 | 44,525 | 120,792 | 33,588 |
| 31 Mar 16 | 366,889 | 50,419 | 118,318 | 33,813 |
| 31 Dec 15 | 365,220 | 53,863 | 117,707 | 34,822 |
| 30 Sep 15 | 366,631 | 40,482 | 117,110 | 40,072 |
| 30 Jun 15 | 362,903 | 39,300 | 119,714 | 42,380 |
| 31 Mar 15 | 353,080 | 30,652 | 119,713 | 42,996 |
| 31 Dec 14 | 353,709 | 24,950 | 121,315 | 43,666 |
| 30 Sep 14 | 355,043 | 31,723 | 126,411 | 43,069 |
| 30 Jun 14 | 348,768 | 37,367 | 123,446 | 42,308 |
| 31 Mar 14 | 354,346 | 33,058 | 126,467 | 41,371 |
| 31 Dec 13 | 351,886 | 42,766 | 126,317 | 40,800 |
Kwaliteitswinsten: RGED.F has high quality earnings.
Groeiende winstmarge: RGED.F's current net profit margins (28.2%) are higher than last year (14.4%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: RGED.F's earnings have grown significantly by 25.4% per year over the past 5 years.
Versnelling van de groei: RGED.F's earnings growth over the past year (85.6%) exceeds its 5-year average (25.4% per year).
Winst versus industrie: RGED.F earnings growth over the past year (85.6%) exceeded the Pharmaceuticals industry 13%.
Rendement op eigen vermogen
Hoge ROE: RGED.F's Return on Equity (19.6%) is considered low.